Fwd: [Use of immunocytochemical assays in the study of exudates from serous cavities in the practical work of a laboratory]

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: [Use of immunocytochemical assays in the study of exudates from serous cavities in the practical work of a laboratory]
To: mesothelioma77@gmail.com


[1]Klin Lab Diagn. 2008 Jan; 20-2, 35-6
Grigoruk OG, Bazulina LM, Lazarev AF

The clinical introduction of new methods for processing fluid samples and the application of supplementary methods for improving the diagnostic accuracy of the pattern of pleurisy is very important for differential diagnosis. The possibilities of using immunocytochemical assay in the practical work of a clinical diagnostic (cytological) laboratory were studied in 96 patients, including 78 and 18 patients with pleural and ascitic fluids, respectively). A Cytospin-IV centrifuge was used for immunocytochemical assay by the routine procedure. The Streptadivin-biotin LSAB2 and EnVision+ test systems were employed to visualize an antigen/antibody reaction. Diaminobenzidine (DAB) was used as a chromogen. A set of markers, comprising 11 antibodies, was applied to the verification of a neoplasm from serous cavities. Mesothelioma was diagnosed in 65 patients. Epithelial mesothelioma was identified in 62 (95.4%) cases. Mesothelioma cells were positive to vimentin and ceratins, calretinin, mesothelin, and thrombomodulin. In 31 cases, adenogenic carcinoma metastases to the serous cavities were typified by an immunopositive reaction to CEA, Ber-EP4, EMA, and cytokeratins and a negative reaction to calretinin, mesothelin, and thrombomodulin. There was occasionally a positive reaction to CD-15 and vimentin.



___
Source: http://www.hubmed.org/display.cgi?uids=18314775
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

More Related Sites:

Private Student Loans: A Parent's Best Choice?

Consolidate Debt Loans: For Better Debt Management

Mortgage Refinancing: The Info You Need Before You Refinance

Low Car Insurance Rate Canada

Florida Dwi Defense

Florida DWI Arrest

97402 Dui Classses

Debt Consolidation UK

School Loan Consolidation

Consolidate Debt Loans: To Eliminate Credit Card Debts

http://www.lingwellness.com/consolidatedebtloans3.php

http://www.lingwellness.com/mortgagerefinancing.php

http://www.lingwellness.com/privatestudentloans.php

 

Fwd: MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.
To: mesothelioma77@gmail.com


[1]Pediatr Radiol. 2008 Mar 21;
Wang ZJ, Boddington S, Wendland M, Meier R, Corot C, Daldrup-Link H

BACKGROUND: Because of its over-expression in many human tumors, the folate receptor (FR) is a promising target for tumor-specific imaging. OBJECTIVE: To evaluate the uptake of FR-targeted gadolinium (P866) and iron-oxide (P1048) agents in an ovarian tumor model. MATERIALS AND METHODS: FR-positive ovarian cancer cells (IGROV-1) were incubated with FR-targeted agents (P866 or P1048) in the absence or presence of competing free folate. Intracellular gadolinium or iron-oxide concentrations were measured. MR imaging of implanted ovarian tumors in rats was performed following injection of FR-targeted (P866 and P1048) and nontargeted (P1001 and P904) agents. Changes in longitudinal and transverse relaxation rates (DeltaR1 and DeltaR2), which were proportional to the contrast agent concentration in the tumors, were compared between tumors injected with FR-targeted and nontargeted agents. RESULTS: IGROV-1 cells showed uptake of P866 and P1048, which decreased with competing free folate. The DeltaR1 values were higher at 1 h following injection of P866 than following injection of P1001 (P

___
Source: http://www.hubmed.org/display.cgi?uids=18357444
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Clinical characteristics of small cell carcinoma of the breast.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: Clinical characteristics of small cell carcinoma of the breast.
To: mesothelioma77@gmail.com


[1]Oncol Rep. 2008 Apr; 19(4): 981-5
Sadanaga N, Okada S, Shiotani S, Morita M, Kakeji Y, Kitamura K, Tamiya S, Sugimachi K, Maehara Y

Primary small cell carcinoma of the breast is a rare tumor of which less than 40 cases have been reported in the literature. Because of its rarity, its biological and clinical characteristics are still not fully understood and, to date, no standard therapy has been developed. Here, we present a case and a review of the literature regarding this cancer, focusing on clinicopathological findings and treatment. Primary small cell carcinoma of the breast differs from more common types of breast cancer in its biological features. It is anticipated that an improved understanding of the clinical characteristics of this tumor will result in the development of new therapeutic modalities, which would improve its prognosis.



___
Source: http://www.hubmed.org/display.cgi?uids=18357385
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Naturally Occurring Small-Molecule Inhibitors of Hedgehog/GLI-Mediated Transcription.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: Naturally Occurring Small-Molecule Inhibitors of Hedgehog/GLI-Mediated Transcription.
To: mesothelioma77@gmail.com


[1]Chembiochem. 2008 Mar 20;
Hosoya T, Arai MA, Koyano T, Kowithayakorn T, Ishibashi M

The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors. To search for Hh/GLI inhibitors, we screened for naturally occurring inhibitors of the transcriptional activator GLI1 by using a cell-based assay. We identified zerumbone (1), zerumbone epoxide (2), staurosporinone (9), 6-hydroxystaurosporinone (10), arcyriaflavin C (11) and 5,6-dihydroxyarcyriaflavin A (12) as inhibitors of GLI-mediated transcription. In addition, we isolated physalins F (17) and B (18) from Physalis minima, which are also potent inhibitors. These compounds also inhibited GLI2-mediated transactivation. Semiquantitative RT-PCR and Western blotting analysis further revealed that 1, 9, 17, and 18 decreased Hh-related component expressions. We also show that inhibitors of GLI-mediated transactivation reduce the level of the antiapoptosis Bcl2 expression. Finally, these identified compounds were cytotoxic to PANC1 pancreatic cancer cells, which express Hh/GLI components. These results strongly suggest that the cytotoxicity of the compounds to PANC1 cells correlates with their inhibition of GLI-mediated transcription.



___
Source: http://www.hubmed.org/display.cgi?uids=18357592
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: McCarter: Vols' transfer glad he's home

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Mar 23, 2008 at 1:39 PM
Subject: McCarter: Vols' transfer glad he's home
To: mesothelioma77@gmail.com

When the camera zooms in tight, you can see the teardrops. Two of them, suspended under his left eye.

Sun, 23 Mar 2008 15:26:56 GMT

---

Source: http://www.al.com/huntsvilletimes/stories/index.ssf?/base/sports/120626373995830.xml&coll=1
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
To: mesothelioma77@gmail.com


[1]Lancet. 2008 Mar 18;


BACKGROUND: The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2.0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefits of radiotherapy schedules using fraction sizes larger than 2.0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy. METHODS: Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2.0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. FINDINGS: 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% CI 1.3-3.1) in the 40 Gy group and 3.3% (95% CI 2.2 to 4.5) in the 50 Gy group, representing an absolute difference of -0.7% (95% CI -1.7% to 0.9%)-ie, the absolute difference in local-regional relapse could be up to 1.7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy. INTERPRETATION: A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.



___
Source: http://www.hubmed.org/display.cgi?uids=18355913
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc